Bio-Bridge Science (BGES) now controls 51% of the outstanding capital stock of the seller. The total cash purchase price for the shares is RMB6 million.
Liang Qiao, chairman and CEO of Bio-Bridge Science, said: “Xinheng Baide fits into our strategic plan by providing a potential steady, while growing, source of revenues to us, as well as providing a new distribution channel for our products.”